Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SIEN
CUSIPN/A
Phone805-562-3500
Debt
Debt-to-Equity Ratio2.31
Current Ratio1.21
Quick Ratio0.71
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.54 million
Price / Sales15.17
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book13.85
Profitability
EPS (Most Recent Fiscal Year)($2.82)
Net Income$-64,020,000.00
Net Margins-164.72%
Return on Equity-181.25%
Return on Assets-65.09%
Miscellaneous
Employees200
Outstanding Shares28,180,000
Market Cap$538.58
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra (NASDAQ:SIEN) issued its earnings results on Wednesday, May, 9th. The medical instruments supplier reported ($0.99) EPS for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.15. The medical instruments supplier had revenue of $14.60 million for the quarter, compared to analysts' expectations of $14.49 million. Sientra had a negative return on equity of 181.25% and a negative net margin of 164.72%. The business's revenue was up 95.2% compared to the same quarter last year. During the same period last year, the business posted $0.61 earnings per share. View Sientra's Earnings History.
What price target have analysts set for SIEN?
7 equities research analysts have issued 12 month target prices for Sientra's shares. Their predictions range from $14.00 to $23.00. On average, they anticipate Sientra's stock price to reach $18.20 in the next twelve months. This suggests that the stock has a possible downside of 7.5%. View Analyst Ratings for Sientra.
What is the consensus analysts' recommendation for Sientra?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Sientra stock?
Here are some recent quotes from research analysts about Sientra stock:
- 1. According to Zacks Investment Research, "Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. " (6/7/2018)
- 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating on Sientra following strong Q1/18 results that came in slightly ahead of prelim results. SIEN has had a busy start to the year executing on key initiatives that leave us incrementally more confident in the company’s ability to deliver upside to estimates moving forward. Specifically, SIEN received FDA approval of the company’s new manufacturing facility and immediately re-entered the US breast implant market early in the Q2, posted a robust Q1 that showed continued momentum in tissue expander sales as well as encouraging signs of a turnaround in the miraDry business, and lastly completed a $108M (net of fees) capital raise." (5/10/2018)
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include CONSORT Med PLC/S (CSRMY), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), Histogenics (HSGX), Rewalk Robotics (RWLK), NanoVibronix (NAOV), COLLPLANT HOLDI/S (CLGN), Precision Therapeutics (AIPT), Bionik Laboratories (BNKL), Allied Healthcare Products (AHPI) and Avitar (AVTI).
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 71)
- Mr. Patrick F. Williams, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 45)
- Mr. Charles Huiner, Chief Operating Officer and Sr. VP of Corp. Devel. & Strategy (Age 47)
- Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.
- Mr. Jason O'Hearn, VP of Sales & Professional Relations
Has Sientra been receiving favorable news coverage?
News coverage about SIEN stock has been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sientra earned a news sentiment score of 0.17 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 46.50 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Sientra's major shareholders?
Sientra's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ABINGWORTH LLP (8.90%) and Columbia Partners L L C Investment Management (0.18%). Company insiders that own Sientra stock include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Institutional Ownership Trends for Sientra.
Which major investors are buying Sientra stock?
SIEN stock was purchased by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management. Company insiders that have bought Sientra stock in the last two years include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Insider Buying and Selling for Sientra.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $19.67.
How big of a company is Sientra?
Sientra has a market capitalization of $538.58 million and generates $36.54 million in revenue each year. The medical instruments supplier earns $-64,020,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Sientra employs 200 workers across the globe.
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (NASDAQ SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
